Hannah Choe, MD

Treatment options for steroid refractory acute GvHD, including ruxolitinib efficacy and NCCN guideline adherence, take center stage in the discussion.

Subject-matter experts delve into the diagnosis, risk assessment, and treatment selection process for acute GvHD, emphasizing differentiation of refractory disease.

Panelists Hannah Choe, MD, and Bart L Scott, MD share insights concerning prophylaxis in Graft-Versus-Host Disease, including key study data and current standards of care as well as discuss the potential role of biomarkers in GvHD.

Moderator Michael Bishop, MD introduces expert panelists and leads an overview of Graft-Versus-Host Disease, covering the differences between chronic and acute conditions, how GvHD is typically diagnosed, and GvHD risk assessment.

Experts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.

A look into the future of chronic GvHD and which treatment options patients the panel is most excited about.

Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.

Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.

Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.

Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.

Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.

A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.

Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice

A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.

Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.

Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.

Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.

Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.

Drs Hannah Choe, Yi-Bin Chen, Nelson J. Chao, and Sophie Paczesny explore emerging treatment options in the pipeline for the treatment of steroid-refractory chronic GVHD.

Hannah Choe, MD, leads the discussion on clinical experiences using off-label regimens to treat steroid-refractory chronic GVHD, and the optimal sequencing of therapy.

Hannah Choe, MD; Sophie Paczesny, MD, PhD; and Nelson J. Chao, MD, MBA, review the use of current FDA approved therapies—ruxolitinib, ibrutinib, and belumosudil—for the treatment of steroid-refractory chronic GVHD.

Yi-Bin Chen, MD, leads a discussion on the use of steroids as first-line treatment of chronic GVHD and when to switch therapy.

Nelson J. Chao, MD, MBA, and Hannah Choe, MD, define steroid-refractory acute GVHD and current treatment options for the disease.

Sophie Paczesny, MD, PhD, provides insight on how strategies to treat acute GVHD have changed over time regarding outcomes and pathophysiology of disease.

Hannah Choe, MD, discusses triggers to initiate acute GVHD therapy and goals of treatment.

Yi-Bin Chen, MD, and Nelson J. Chao, MD, MBA, comment on the changing landscape of GVHD and the effect on patient outcomes.

Sophie Paczesny, MD, PhD; Yi-Bin Chen, MD; and Hannah Choe, MD, review recent advances in GVHD prophylaxis as presented at the 2021 American Society of Hematology (ASH) Annual Meeting and Symposium.

Nelson J. Chao, MD, MBA, reviews current GVHD prophylaxis options and factors to consider when selecting one for a given patient.

Hannah Choe, MD; Nelson J. Chao, MD, MBA; and Sophie Paczesny, MD, PhD, comment on the importance of early detection of disease and the role of biomarker testing in GVHD.